Repros
Therapeutics Inc. (Nasdaq: RPRX) reported positive results from a study of
its secondary hypogonadism treatment Androxal and announced that the
Food and Drug Administration granted a Type B Pre-NDA meeting to discuss
the company's planned New Drug Application for Androxal. The stock price soared $1.52 to close at $10.48.
Repros Therapeutics reports positive study results
September 26, 2014 at 20:06 PM EDT